Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASEAssignment of Sublease and Sub-Sublease • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASE (this “Assignment”) is made as of December 13, 2019 by and between Casebia Therapeutics LLC (“Assignor”) and CRISPR Therapeutics, Inc. (“Assignee”).
